UBS Raises Price Target on Premier (PINC) Following Announced Essensa Ventures Acquisition

November 29, 2016 9:24 AM EST
Get Alerts PINC Hot Sheet
Price: $31.18 +1.27%

Rating Summary:
    15 Buy, 3 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 20 | Down: 35 | New: 11
Trade PINC Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

UBS reiterated a Neutral rating on Premier, Inc. (NASDAQ: PINC), and raised the price target to $33.00 (from $32.50), following the company's announced acquisition of Essensa Ventures for $325MM. The deal is consistent with Premier's goal to expand its GPO presence across the continuum of care, specifically in the non-acute space.

Analyst Michael Cherny commented, "Innovatix and Essensa Ventures are two continuum of care GPOs (institutional healthcare providers outside the acute care hospital or health system), and Premier currently owns a 50% interest in the former. Innovatix currently serves more than 32,000 facilities (senior living facilities, independent medical oncologists, pharmacies, etc). Essensa is a national GPO serving ambulatory care, surgery centers, clinical laboratories, and other alternate sites of care. The company expects the acquisition to be immediately accretive. Premier expects the deal to contribute ~$53-$60MM to revenue, $18-$21MM to EBITDA and $0.04-$0.06 to EPS in FY17."

For an analyst ratings summary and ratings history on Premier, Inc. click here. For more ratings news on Premier, Inc. click here.

Shares of Premier, Inc. closed at $29.82 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change, Mergers and Acquisitions

Related Entities

UBS, Definitive Agreement

Add Your Comment